Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | http://hdl.handle.net/1843/44821 |
Resumo: | Objectives To assess the association between oral mucosa hyperpigmentation in patients with leukemia and imatinib mesylate use. Additionally, we compared our data to those obtained from a systematic review. Materials and methods A cross-sectional study was conducted with 74 patients undergoing treatment with imatinib mesylate. Sociodemographic characteristics, oral mucosa alterations, and medical history were evaluated. Oral hyperpigmentation was scored. The use of imatinib mesylate and hydroxyurea was evaluated. Association between oral hyperpigmentation and imatinib mesylate was assessed. A systematic review was also conducted to retrieve case reports or case series of patients with oral hyperpigmentation associated with imatinib mesylate. Results Among the 74 participants, 41 were male (55.4%) and 33 were female (44.6%). Participants’ mean age was 49.3 years. Sixty-six (89.2%) patients developed hyperpigmented lesions in the hard palate mucosa. In multivariate analysis, patients who had used imatinib mesylate for > 72 months had a hyperpigmentation score 1.62 times higher than those who had used this medication during a shorter period. Patients who had used hydroxyurea for > 30 days had a hyperpigmentation score 1.43 times higher than those who had used this medication during a shorter period. The systematic review retrieved 20 clinical cases of patients undergoing imatinib mesylate treatment and exhibiting oral hyperpigmentation. Conclusions The development of oral hyperpigmentation is associated with imatinib mesylate use. Hydroxyurea seems to increment such an association. Clinical relevance To assist providers in the differential diagnosis of hyperpigmented lesions associated with imatinib mesylate, as well as in the clinical management of such lesions. |
id |
UFMG_470ba6a2e64200a51ca17128f2719b70 |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/44821 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
2022-09-01T20:02:12Z2022-09-01T20:02:12Z201910.1007/s00784-019-02886-01436-3771http://hdl.handle.net/1843/44821Objectives To assess the association between oral mucosa hyperpigmentation in patients with leukemia and imatinib mesylate use. Additionally, we compared our data to those obtained from a systematic review. Materials and methods A cross-sectional study was conducted with 74 patients undergoing treatment with imatinib mesylate. Sociodemographic characteristics, oral mucosa alterations, and medical history were evaluated. Oral hyperpigmentation was scored. The use of imatinib mesylate and hydroxyurea was evaluated. Association between oral hyperpigmentation and imatinib mesylate was assessed. A systematic review was also conducted to retrieve case reports or case series of patients with oral hyperpigmentation associated with imatinib mesylate. Results Among the 74 participants, 41 were male (55.4%) and 33 were female (44.6%). Participants’ mean age was 49.3 years. Sixty-six (89.2%) patients developed hyperpigmented lesions in the hard palate mucosa. In multivariate analysis, patients who had used imatinib mesylate for > 72 months had a hyperpigmentation score 1.62 times higher than those who had used this medication during a shorter period. Patients who had used hydroxyurea for > 30 days had a hyperpigmentation score 1.43 times higher than those who had used this medication during a shorter period. The systematic review retrieved 20 clinical cases of patients undergoing imatinib mesylate treatment and exhibiting oral hyperpigmentation. Conclusions The development of oral hyperpigmentation is associated with imatinib mesylate use. Hydroxyurea seems to increment such an association. Clinical relevance To assist providers in the differential diagnosis of hyperpigmented lesions associated with imatinib mesylate, as well as in the clinical management of such lesions.Objetivos Avaliar a associação entre hiperpigmentação da mucosa oral em pacientes com leucemia e mesilato de imatinibe usar. Além disso, comparamos nossos dados com os obtidos em uma revisão sistemática. Materiais e métodos Foi realizado um estudo transversal com 74 pacientes em tratamento com mesilato de imatinibe. Foram avaliadas características sociodemográficas, alterações da mucosa oral e histórico médico. A hiperpigmentação oral foi marcou. Foi avaliado o uso de mesilato de imatinibe e hidroxiureia. Associação entre hiperpigmentação oral e imatinibe mesilato foi avaliado. Uma revisão sistemática também foi realizada para recuperar relatos de casos ou séries de casos de pacientes com hiperpigmentação associada ao mesilato de imatinibe. Resultados Entre os 74 participantes, 41 eram do sexo masculino (55,4%) e 33 do sexo feminino (44,6%). A média de idade dos participantes foi de 49,3 anos. Sessenta e seis (89,2%) pacientes desenvolveram lesões hiperpigmentadas na mucosa do palato duro. Na análise multivariada, os pacientes que usaram mesilato de imatinibe por > 72 meses tiveram um escore de hiperpigmentação 1,62 vezes maior do que aqueles que usaram este medicação durante um período mais curto. Pacientes que usaram hidroxiureia por > 30 dias apresentaram escore de hiperpigmentação 1,43 vezes maior do que aqueles que usaram esse medicamento por um período menor. A revisão sistemática recuperou 20 casos clínicos de pacientes submetidos a tratamento com mesilato de imatinibe e exibindo hiperpigmentação oral. Conclusões O desenvolvimento de hiperpigmentação oral está associado ao uso de mesilato de imatinibe. A hidroxiureia parece incrementar tal associação. Relevância clínica Para auxiliar os profissionais no diagnóstico diferencial de lesões hiperpigmentadas associadas ao mesilato de imatinibe, bem como no manejo clínico dessas lesões.engUniversidade Federal de Minas GeraisUFMGBrasilFAO - DEPARTAMENTO DE ODONTOLOGIA SOCIAL E PREVENTIVAFAO - DEPARTAMENTO DE ODONTOPEDIATRIA E ORTODONTIAClinical oral investigationsFarmacologiaPatologia BucalAgentes AntineoplásicosMesilato de ImatinibeHidroxiureiaHiperpigmentação OralAssociation of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature reviewAssociação da hiperpigmentação da mucosa oral com o uso de mesilato de imatinibe: estudo transversal e revisão sistemática da literaturainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://www.odonto.ufmg.br/cenex/wp-content/uploads/sites/2/2021/09/Association-of-oral-mucosa-hyperpigmentation-with-imatinib-mesylate-use-a-cross-sectional-study-and-a-systematic-literature-review-1-1.pdfSicília Rezende OliveiraLuciana Gravito de Azevedo BrancoAmanda Leal RochaDenise Vieira TravassosGustavo Henrique Romani MagalhãesFelipe Paiva FonsecaRicardo Alves MesquitaLucas Guimarães AbreuTarcília Aparecida da Silvaapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/44821/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINAL2019_Association of oral mucosa hyperpigmentation with imatinib mesylate use-a cross-sectional study and a systematic literature review.pdf2019_Association of oral mucosa hyperpigmentation with imatinib mesylate use-a cross-sectional study and a systematic literature review.pdfapplication/pdf3332774https://repositorio.ufmg.br/bitstream/1843/44821/2/2019_Association%20of%20oral%20mucosa%20hyperpigmentation%20with%20imatinib%20mesylate%20use-a%20cross-sectional%20study%20and%20a%20systematic%20literature%20review.pdf28a0e18b1ffe17ab1332f7803cab27e2MD521843/448212022-09-01 17:02:12.729oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2022-09-01T20:02:12Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.pt_BR.fl_str_mv |
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review |
dc.title.alternative.pt_BR.fl_str_mv |
Associação da hiperpigmentação da mucosa oral com o uso de mesilato de imatinibe: estudo transversal e revisão sistemática da literatura |
title |
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review |
spellingShingle |
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review Sicília Rezende Oliveira Farmacologia Patologia Bucal Agentes Antineoplásicos Mesilato de Imatinibe Hidroxiureia Hiperpigmentação Oral |
title_short |
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review |
title_full |
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review |
title_fullStr |
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review |
title_full_unstemmed |
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review |
title_sort |
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review |
author |
Sicília Rezende Oliveira |
author_facet |
Sicília Rezende Oliveira Luciana Gravito de Azevedo Branco Amanda Leal Rocha Denise Vieira Travassos Gustavo Henrique Romani Magalhães Felipe Paiva Fonseca Ricardo Alves Mesquita Lucas Guimarães Abreu Tarcília Aparecida da Silva |
author_role |
author |
author2 |
Luciana Gravito de Azevedo Branco Amanda Leal Rocha Denise Vieira Travassos Gustavo Henrique Romani Magalhães Felipe Paiva Fonseca Ricardo Alves Mesquita Lucas Guimarães Abreu Tarcília Aparecida da Silva |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Sicília Rezende Oliveira Luciana Gravito de Azevedo Branco Amanda Leal Rocha Denise Vieira Travassos Gustavo Henrique Romani Magalhães Felipe Paiva Fonseca Ricardo Alves Mesquita Lucas Guimarães Abreu Tarcília Aparecida da Silva |
dc.subject.other.pt_BR.fl_str_mv |
Farmacologia Patologia Bucal Agentes Antineoplásicos Mesilato de Imatinibe Hidroxiureia Hiperpigmentação Oral |
topic |
Farmacologia Patologia Bucal Agentes Antineoplásicos Mesilato de Imatinibe Hidroxiureia Hiperpigmentação Oral |
description |
Objectives To assess the association between oral mucosa hyperpigmentation in patients with leukemia and imatinib mesylate use. Additionally, we compared our data to those obtained from a systematic review. Materials and methods A cross-sectional study was conducted with 74 patients undergoing treatment with imatinib mesylate. Sociodemographic characteristics, oral mucosa alterations, and medical history were evaluated. Oral hyperpigmentation was scored. The use of imatinib mesylate and hydroxyurea was evaluated. Association between oral hyperpigmentation and imatinib mesylate was assessed. A systematic review was also conducted to retrieve case reports or case series of patients with oral hyperpigmentation associated with imatinib mesylate. Results Among the 74 participants, 41 were male (55.4%) and 33 were female (44.6%). Participants’ mean age was 49.3 years. Sixty-six (89.2%) patients developed hyperpigmented lesions in the hard palate mucosa. In multivariate analysis, patients who had used imatinib mesylate for > 72 months had a hyperpigmentation score 1.62 times higher than those who had used this medication during a shorter period. Patients who had used hydroxyurea for > 30 days had a hyperpigmentation score 1.43 times higher than those who had used this medication during a shorter period. The systematic review retrieved 20 clinical cases of patients undergoing imatinib mesylate treatment and exhibiting oral hyperpigmentation. Conclusions The development of oral hyperpigmentation is associated with imatinib mesylate use. Hydroxyurea seems to increment such an association. Clinical relevance To assist providers in the differential diagnosis of hyperpigmented lesions associated with imatinib mesylate, as well as in the clinical management of such lesions. |
publishDate |
2019 |
dc.date.issued.fl_str_mv |
2019 |
dc.date.accessioned.fl_str_mv |
2022-09-01T20:02:12Z |
dc.date.available.fl_str_mv |
2022-09-01T20:02:12Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/44821 |
dc.identifier.doi.pt_BR.fl_str_mv |
10.1007/s00784-019-02886-0 |
dc.identifier.issn.pt_BR.fl_str_mv |
1436-3771 |
identifier_str_mv |
10.1007/s00784-019-02886-0 1436-3771 |
url |
http://hdl.handle.net/1843/44821 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Clinical oral investigations |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.publisher.initials.fl_str_mv |
UFMG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
FAO - DEPARTAMENTO DE ODONTOLOGIA SOCIAL E PREVENTIVA FAO - DEPARTAMENTO DE ODONTOPEDIATRIA E ORTODONTIA |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/44821/1/License.txt https://repositorio.ufmg.br/bitstream/1843/44821/2/2019_Association%20of%20oral%20mucosa%20hyperpigmentation%20with%20imatinib%20mesylate%20use-a%20cross-sectional%20study%20and%20a%20systematic%20literature%20review.pdf |
bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 28a0e18b1ffe17ab1332f7803cab27e2 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
|
_version_ |
1803589215657656320 |